

FORM 7**MONTHLY PROGRESS REPORT**Name of Listed Issuer: Abattis Bioceuticals Corp. (the "Issuer").Trading Symbol: ATTNumber of Outstanding Listed Securities: 477,804,139 common sharesDate: February 4, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On January 10, 2019, the Issuer announced that, further to its news release dated December 7, 2018, the Company has entered into a definitive share exchange agreement (the "Agreement") with 1157016 B.C. Ltd., dba NutriVida, a private arm's length company incorporated in the Province of British Columbia ("NutriVida"), pursuant to which the Company will acquire

100% of the issued and outstanding common shares of NutriVida (the “Acquisition”).

For more information regarding the Acquisition, see the Issuer’s news release dated January 11, 2019.

On January 17, 2019, the Issuer announced that the temporary order from the British Columbia Securities Commission, issued on November 26, 2018 (the “Order”), has not been extended against the Issuer.

For more information regarding the Order, see the Issuer’s news release dated January 17, 2019.

On January 18, 2019, the Issuer announced that on January 17, 2019, after the announcement of the Company’s proposed Acquisition, the Company received a letter from a third party making certain claims concerning the wrongful use, by NutriVida, of certain proprietary fertilizer formulations (the “Claims”). At this time, no formal legal proceedings have been initiated against NutriVida or the Issuer in relation to the Claims.

For more information regarding the Claims, see the Issuer’s news release dated January 18, 2019.

2. Provide a general overview and discussion of the activities of management.

See Item 1

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See Item 1.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

See Item 1.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

On January 14, 2019, the Issuer posted and amended Form 9 disclosing the issuance of an aggregate of 1,027,084 common shares (each, a "Share") at a price of \$0.06 per Share in connection with the settlement of debt on the books of the Issuer in the aggregate of \$61,625 (the "Debt Settlement").

For more information regarding the Debt Settlement, see the Issuer's Form 9 dated January 14, 2019 posted on the Exchange's website at <https://thecse.com/en/listings/life-sciences/abattis-bioceuticals-corp>

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

See Item 1.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

See Item 1.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 4, 2019.

Kent McParland

Name of Director or Senior
Officer

"Kent McParland"
Signature

DocuSigned by:
Kent McParland
0330BC23038B4FA...

CFO

Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		End	YY/MM/DD
Abattis Biocetical Corp.		January 2019	2019/02/04
Issuer Address			
1200 - 625 Howe Street			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6Z 2T6		604.608.5688	808.650.3007
Contact Name		Contact	Contact Telephone No.
Kent McParland		Position	
		CFO	808.650.3007
Contact Email Address		Web Site Address	
kent@abattis.com		www.abattis.com	

FORM 7 – MONTHLY PROGRESS REPORT

January 2015
Page 5